All Phenotypes Mob1a<tm1.1Asuz> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Mob1a^tm1.1Asuz
targeted mutation 1.1, Akira Suzuki
MGI:5473804

Summary

7 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	B6.Cg-Mob1b^{Gt(CC0690)Wtsi} Mob1a^tm1.1Asuz Speer6-ps1^{Tg(Alb-cre)21Mgn}	MGI:5897809
cn2	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Alb^{tm1(cre/ERT2)Mtz}/Alb⁺	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5897810
cn3	Ccn2^tm1.1Alea/Ccn2^tm1.1Alea Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA	MGI:5897813
cn4	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Yap1^{tm1c(KOMP)Mbp}/Yap1^{tm1c(KOMP)Mbp} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * DBA	MGI:5897815
cn5	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(KRT14-cre/ERT)20Efu/0	involves: 129P2/OlaHsd * C57BL/6 * CD-1	MGI:5473848
cn6	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Wwtr1^tm1Hku/Wwtr1^tm1Hku Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129P2/OlaHsd * C57BL/6 * DBA	MGI:5897811
cn7	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ Tgfbr2^tm1Roes/Tgfbr2^tm1Roes	involves: 129P2/OlaHsd * C57BL/6 * DBA	MGI:5897816

Allelic Composition	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	B6.Cg-Mob1b^{Gt(CC0690)Wtsi} Mob1a^tm1.1Asuz Speer6-ps1^{Tg(Alb-cre)21Mgn}

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mob1a^tm1.1Asuz mutation (0 available); any Mob1a mutation (18 available)
Mob1b^{Gt(CC0690)Wtsi} mutation (0 available); any Mob1b mutation (21 available)
Speer6-ps1^{Tg(Alb-cre)21Mgn} mutation (6 available); any Speer6-ps1 mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:228499 )

• all mice are dead by 60 weeks

postnatal lethality, incomplete penetrance ( J:228499 )

• the first mice die at P14 and more than half of mice die by P21

liver/biliary system

liver/biliary system phenotype ( J:228499 )

N	• mice exhibit normal liver structure at P0

increased hepatocyte proliferation ( J:228499 )

• 3 times in controls

abnormal cholangiocyte morphology ( J:228499 )

• at P7, mice exhibit increased immature cholangiocyte-like and oval cells that becomes massive at P10 especially in periductal and intraductal locations

• mild hepatocholangiocellular hyperplasia at P21

enlarged liver ( J:228499 )

• massive

increased hepatocyte number ( J:228499 )

• 5 times greater than in control mice at P14

liver fibrosis ( J:228499 )

increased hepatobiliary system tumor incidence ( J:228499 )

• combined hepatocellular and cholangiocarcinomas, increased hepatocellular carcinoma, liver adenoma incidence or cholangiocarcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• combined hepatocellular and cholangiocarcinomas in 13 of 22 mice at week 60

• with lung metastasis after 40 weeks of age

increased cholangiocarcinoma incidence ( J:228499 )

• intrahepatic cholangiocellular carcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• in 2 of 22 mice at week 60

increased hepatocellular carcinoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

• in 4 of 22 mice at week 60

increased liver adenoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

abnormal bile duct physiology ( J:228499 )

• cholangiocytes proliferation is increased 4 times compared with controls

• however, there is no increase in apoptosis

jaundice ( J:228499 )

neoplasm

increased hepatobiliary system tumor incidence ( J:228499 )

• combined hepatocellular and cholangiocarcinomas, increased hepatocellular carcinoma, liver adenoma incidence or cholangiocarcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• combined hepatocellular and cholangiocarcinomas in 13 of 22 mice at week 60

• with lung metastasis after 40 weeks of age

increased cholangiocarcinoma incidence ( J:228499 )

• intrahepatic cholangiocellular carcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• in 2 of 22 mice at week 60

increased hepatocellular carcinoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

• in 4 of 22 mice at week 60

increased liver adenoma incidence ( J:228499 )

• in mice surviving beyond P21 by age 15 weeks

homeostasis/metabolism

increased circulating bilirubin level ( J:228499 )

integument

abdomen swellings ( J:228499 )

• due to enlarged liver

cellular

increased hepatocyte proliferation ( J:228499 )

• 3 times in controls

endocrine/exocrine glands

abnormal cholangiocyte morphology ( J:228499 )

• at P7, mice exhibit increased immature cholangiocyte-like and oval cells that becomes massive at P10 especially in periductal and intraductal locations

• mild hepatocholangiocellular hyperplasia at P21

increased cholangiocarcinoma incidence ( J:228499 )

• intrahepatic cholangiocellular carcinoma in 8 of 10 mice surviving beyond P21 by age 15 weeks

• in 2 of 22 mice at week 60

growth/size/body

enlarged liver ( J:228499 )

• massive

Allelic Composition	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Alb^{tm1(cre/ERT2)Mtz}/Alb⁺
Genetic Background	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Alb^{tm1(cre/ERT2)Mtz} mutation (2 available); any Alb mutation (97 available)
Mob1a^tm1.1Asuz mutation (0 available); any Mob1a mutation (18 available)
Mob1b^{Gt(CC0690)Wtsi} mutation (0 available); any Mob1b mutation (21 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

increased hepatobiliary system tumor incidence ( J:228499 )

• at 5 weeks, tamoxifen-treated mice exhibit milder combined hepatocellular and cholangiocarcinomas, hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma compared with conditional mice with Tg(Alb-cre)21Mgn transgene

neoplasm

increased hepatobiliary system tumor incidence ( J:228499 )

Allelic Composition	Ccn2^tm1.1Alea/Ccn2^tm1.1Alea Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ccn2^tm1.1Alea mutation (1 available); any Ccn2 mutation (29 available)
Mob1a^tm1.1Asuz mutation (0 available); any Mob1a mutation (18 available)
Mob1b^{Gt(CC0690)Wtsi} mutation (0 available); any Mob1b mutation (21 available)
Speer6-ps1^{Tg(Alb-cre)21Mgn} mutation (6 available); any Speer6-ps1 mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

increased liver weight ( J:228499 )

• as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

liver fibrosis ( J:228499 )

• as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

endocrine/exocrine glands

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

growth/size/body

increased liver weight ( J:228499 )

• as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

Allelic Composition	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Yap1^{tm1c(KOMP)Mbp}/Yap1^{tm1c(KOMP)Mbp} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * DBA

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells but far less than in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

increased liver weight ( J:228499 )

• much less than in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

liver fibrosis ( J:228499 )

• much less than in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

endocrine/exocrine glands

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells but far less than in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

growth/size/body

increased liver weight ( J:228499 )

• much less than in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

Allelic Composition	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(KRT14-cre/ERT)20Efu/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * CD-1

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Skin and hair abnormalities and large paws in tamoxifen treated Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Tg(KRT14-cre/ERT)20Efu/0 Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} mice

mortality/aging

premature death ( J:193981 )

• mice treated with tamoxifen at P28 die within 15 to 55 days of treatment

postnatal lethality, complete penetrance ( J:193981 )

• early tamoxifen-treated results in death within 10 to 30 days of birth due to malnutrition

integument

ruffled hair ( J:193981 )

• in tamoxifen-treated mice

parakeratosis ( J:193981 )

• in tamoxifen-treated mice

abnormal keratinocyte morphology ( J:193981 )

• increased centrosome number in keratinocytes from tamoxifen-treated mice

• keratinocytes from tamoxifen-treated mice exhibit multi-polar spindles unlike cells from control mice

• micronuclei in keratinocytes from tamoxifen-treated mice

epidermal hyperplasia ( J:193981 )

• at P16, tamoxifen-treated mice exhibit multilayered hyperplastic epithelium in the interfollicular epidermis and hair follicles and impaired epidermal regression during catagen unlike control mice

wrinkled skin ( J:193981 )

• wrinkle-bear facial skin in tamoxifen-treated mice

increased epidermal stem cell number ( J:193981 )

• in the interfollicular epidermis of tamoxifen-treated mice

abnormal keratinocyte physiology ( J:193981 )

• impaired contact inhibition in keratinocytes from tamoxifen-treated mice

decreased keratinocyte apoptosis ( J:193981 )

• in tamoxifen-treated mice

increased keratinocyte proliferation ( J:193981 )

• 1.5 times in tamoxifen-treated mice at P13

• keratinocyte hyperplasia in mice treated with tamoxifen at P28

cellular

abnormal cell nucleus morphology ( J:193981 )

• micronuclei in keratinocytes from tamoxifen-treated mice

abnormal mitosis ( J:193981 )

• accelerated mitotic exit in keratinocytes from tamoxifen-treated mice

abnormal mitotic spindle morphology ( J:193981 )

• keratinocytes from tamoxifen-treated mice exhibit multi-polar spindles unlike cells from control mice

decreased keratinocyte apoptosis ( J:193981 )

• in tamoxifen-treated mice

increased keratinocyte proliferation ( J:193981 )

• 1.5 times in tamoxifen-treated mice at P13

• keratinocyte hyperplasia in mice treated with tamoxifen at P28

craniofacial

abnormal mouth morphology ( J:193981 )

• tamoxifen-treated mice exhibit hyperplasia of the oral cavity unlike control mice

abnormal lip morphology ( J:193981 )

• tamoxifen-treated mice exhibit hyperplastic and enlarged lips compared with control mice

behavior/neurological

dysphagia ( J:193981 )

• in tamoxifen-treated mice

growth/size/body

abnormal mouth morphology ( J:193981 )

• tamoxifen-treated mice exhibit hyperplasia of the oral cavity unlike control mice

abnormal lip morphology ( J:193981 )

• tamoxifen-treated mice exhibit hyperplastic and enlarged lips compared with control mice

decreased body size ( J:193981 )

• in tamoxifen-treated mice

hearing/vestibular/ear

abnormal ear morphology ( J:193981 )

• tamoxifen-treated mice exhibit hyperplastic and enlarged ears compared with control mice

limbs/digits/tail

abnormal autopod morphology ( J:193981 )

• tamoxifen-treated mice exhibit hyperplastic and enlarged front paws compared with control mice

digestive/alimentary system

dysphagia ( J:193981 )

• in tamoxifen-treated mice

Allelic Composition	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Wwtr1^tm1Hku/Wwtr1^tm1Hku Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells but not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

increased liver weight ( J:228499 )

• not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

liver fibrosis ( J:228499 )

• not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

endocrine/exocrine glands

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells but not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

growth/size/body

increased liver weight ( J:228499 )

• not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

Allelic Composition	Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ Tgfbr2^tm1Roes/Tgfbr2^tm1Roes
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells but not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

increased liver weight ( J:228499 )

• not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

liver fibrosis ( J:228499 )

• not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

endocrine/exocrine glands

abnormal cholangiocyte morphology ( J:228499 )

• increased immature cholangiocyte-like and oval cells but not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

growth/size/body

increased liver weight ( J:228499 )

• not as much as in Mob1a^tm1.1Asuz/Mob1a^tm1.1Asuz Mob1b^{Gt(CC0690)Wtsi}/Mob1b^{Gt(CC0690)Wtsi} Tg(Alb-cre)21Mgn mice

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/12/2024 MGI 6.24